Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Part of paid clinical trials in Columbia, Missouri.

Sponsor
University of Missouri-Columbia
Study ID
NCT03551951
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Test for circulating tumor cells, DNA alterations — DIAGNOSTIC_TEST

Study Details

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.

Key Dates

Start date
Jul 1, 2016
Status verified
Oct 2025
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027

Study Design

Enrollment
320 participants (estimated)

Arms

  • Arm: Patients having surgery
    Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
  • Arm: Patients not having surgery
    Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations. Lung cancer screening subjects
  • Arm: Healthy subjects
    Healthy control subjects will have test for circulating tumor cells, DNA alterations

Primary Outcome Measure

Number of CTC/DTC in blood [ Time Frame: At baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Harry S Truman Veterans Memorial HospitalColumbiaMissouri65212
Jussuf Kaifi, MD
573-882-6956

Find similar trials in Columbia, MO

Related Studies